Study: Medtronic's flawed Sprint Fidelis defibrillator leads can be safely extracted
This article was originally published in Clinica
Executive Summary
Medtronic's fracture-prone Sprint Fidelis defibrillator leads can be safely removed from patients, a trial has shown. Current guidelines recommend against prophylactic extraction of the Sprint Fidelis leads due to the procedure's high complication rate.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.